<DOC>
	<DOCNO>NCT00334035</DOCNO>
	<brief_summary>For schizophrenic patient remain remission maintenance medication , may come point time relative risk relapse become low discontinuation therapy consider . This study investigate whether point time reach 12 month follow first episode illness . Moreover , also aim identify predictor relapse well evaluate cost benefit maintenance therapy .</brief_summary>
	<brief_title>Antipsychotic Therapy First Episode</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Male female patient , 18 65 year age Visit 1 Patients must achieve level understand expressive capacity sufficient communicate adequately study coordinator participate cognitive testing . Patients must agree cooperate test examination require protocol . They must willing comply fully treatment Patient must understand nature study must sign informed consent document . Patients must Cantonese speak Han Chinese Patients must diagnose , accord SCID DSMIV , schizophrenia , schizoaffective disorder schizophreniform psychosis . Patients must good response antipsychotic treatment achieve rating 2 Clinical Global Impression Scale ( CGI ) Severity illness ; rating 4 Improvement scale , rating 3 ( conceptual disorganization , unusual thought content ) , rating 2 ( delusion , hallucinatory behavior ) rating 4 ( Suspiciousness ) Positive Negative Syndrome Scale ( PANSS ) least 8 week Female patient either pregnant lactating . Patients previously clozapine exclude study Significant medical illness include seizure . DSMIV substance ( alcohol drug ) abuse dependence within past 3 month . Judged clinically serious suicidal risk . Treatment injectable depot neuroleptic within less one patient 's dosing interval depot neuroleptic injection prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>